1Makris A, Powles T J, Dowsett M, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast cancers[J]. Clin Cancer Res, 1997, 3: 593.
2Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomized trials[J]. Lancet, 1996, 348: 1189.
3Meakin J W, Hayward J L, Panzarella T, et al. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast[J]. Breast Cancer Res Treat, 1996,37: 11.
4Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy[J]. Lancet, 1992, 339: 1.
5Donald L, Wickerham. Average annual rates of invasive and noninvasive breast cancer by history of LCIS and atypical hyperplasia for participants in the BCPT[C]. NSAB P-P1 ASCO # 327.
6Bocea F, Rubagotti A, Perrotta A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre- perimenopausal patients with advanced breast cancer; results of amulticentric italian study[J]. Ann Oncol, 1994, 5: 337.
7Blamey R W, Jonat W, Kaufmann M, et al. Goserelin depot in the treatment of premenopausal advanced breast cancer[J ].Eur J Cancer, 1992, 28A: 810.
8Kaufmann M. Zoladex'(goserelin) vs CMF as adjuvant therapy in pre-/perimenopausal, node-positive early breast cancer:preliminary efficacy results from the ZEBRA study. 7th international conference on adjuvant therapy of primary breast cancer[M], St Ganllen, Switzerland, 2001. 21.
9Yamashita J, Hideshima T, Shirakusa T, et al. Medroxyprogesterone acetate treatment reduces serum interleukin-σ levels in patients with metastatic breast carcinoma [J ]. Cancer,1996, 78: 2346.
10Kurebayashi J, Kurosumi M, Sonoo H. A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifieations in nude mice[J]. Br J Cancer, 1996, 74: 200.
